Hepatitis C: New therapeutic strategies needed for advanced disease

Nature Reviews Gastroenterology and Hepatology

Volumn 6, Issue 6, 2009, Pages 325-327

  Hofmann, Wolf P ^a   Zeuzem, Stefan ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; COLCHICINE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; RIBAVIRIN; SILYMARIN; VIRUS RNA;

ARTICLE; BONE MARROW TOXICITY; CANCER RISK; CLINICAL TRIAL; DEATH; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DISEASE COURSE; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER DISEASE; LIVER FIBROSIS; LONG TERM CARE; LOW DRUG DOSE; MAINTENANCE THERAPY; PRIORITY JOURNAL; RETREATMENT; UNSPECIFIED SIDE EFFECT;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; HEPATITIS C, CHRONIC; HUMANS; LIVER NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 67149105518     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2009.63     Document Type: Article

References (10)

1. Di Bisceglie, A. M. et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N. Engl. J. Med. 359 2429-2441 (2008).
2. Poynard, T. et al. Impact of pegylated interferon α-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122, 1303-1313 (2002).
3. Veldt, B. J. et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann. Intern. Med. 147, 677-684 (2007).
4. Mallet, V. et al. Brief communication: The relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann. Intern. Med. 149, 399-403 (2008).
5. Afdhal, N. H. et al. Colchicine versus PEG-interferon alfa 2b long term therapy: Results of the 4 year copilot trial. J. Hepatol. 48, S4 (2008).
6. Poynard, T. et al. Sustained virologic response (SVR) in the EPIC3 trial: Week twelve virology predicts SVR in previous interferon/ ribavirin treatment failures receiving peg-intron/rebetol (PR) weight based dosing (WBD). J. Hepatol. 42, 40-41 (2005).
7. Papatheodoridis, G. V., Papadimitropoulos, V. C. & Hadziyannis, S. J. effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: A meta-analysis. Aliment. Pharmacol. Ther. 15, 689-698 (2001).
8. Camma, C., Giunta, M., Andreone, P. & Craxi, A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach. J. Hepatol. 34, 593-602 (2001).
9. Seeff, L. B. et al. Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology 47, 605-612 (2008).
10. Zeuzem, S. Interferon-based therapy for chronic hepatitis C: Current and future perspectives. Nat. Clin. Pract. Gastroenterol. Hepatol. 5, 610-622 (2008).